Fountain Therapeutics
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$5.0m | Series A | ||
* | $6.0m | Series A | |
$15.0m | Series A | ||
Total Funding | €23.6m |
Related Content
Recent News about Fountain Therapeutics
EditFountain Therapeutics operates at the intersection of biotechnology and artificial intelligence, focusing on the development of therapeutics that target cellular resilience to combat chronic degenerative diseases. The company leverages its proprietary AI-driven technology, which incorporates advanced machine learning and computer vision, to model and modify cellular health. Fountain's primary clients include healthcare providers, pharmaceutical companies, and research institutions. Operating within the biotech and healthcare markets, Fountain employs a business model centered around the research and development of novel therapeutics, which it monetizes through partnerships, licensing agreements, and direct sales of its therapeutic solutions. The company aims to address the underlying causes of aging-related diseases, offering innovative treatments that improve both the quality and length of life.
Keywords: AI-driven therapeutics, cellular resilience, chronic diseases, degenerative diseases, biotechnology, machine learning, computer vision, healthcare, pharmaceutical, research institutions.